Literature DB >> 9114823

Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.

W D Stein1.   

Abstract

Most cancer deaths result from the cancer's either being intrinsically resistant to chemotherapeutic drugs or becoming resistant after being initially sensitive. Often, in cells grown in cell culture, drug resistance correlates with the presence of one or more of the so-called P-glycoproteins or multidrug resistance proteins, products of the mdr family of genes. This review is largely concerned with the transport kinetics of the P-glycoproteins. We first present a brief overview of the P-glycoproteins, their properties, and their clinical significance. Later sections of the review expand on this material with special emphasis on the substrates of P-glycoprotein and how they cross the cell membrane, on the transport kinetics of the P-glycoprotein, on reversers of its action, and on its activity as an ATPase. In a final section, we consider the mechanism of action of P-glycoprotein as an actively transporting membrane pump. The characteristic of P-glycoprotein considered the most difficult to explain is its very broad specificity (or lack of specificity), but there are precedents for this property in well-known proteins such as serum albumin, which binds a range of molecular types, including substrates and reversers of P-glycoprotein, seemingly as broad as does P-glycoprotein. Pointing out this analogy does not provide a molecular explanation for the substrate-binding properties of P-glycoprotein but does make those properties more assimilable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114823     DOI: 10.1152/physrev.1997.77.2.545

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  33 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.

Authors:  E Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.

Authors:  Guido J E J Hooiveld; Janette Heegsma; Jessica E van Montfoort; Peter L M Jansen; Dirk K F Meijer; Michael Müller
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

4.  In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.

Authors:  Y Chen; S M Simon
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

5.  The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Authors:  Thuy Thanh Tran; Aditya Mittal; Tanya Aldinger; Joseph W Polli; Andrew Ayrton; Harma Ellens; Joe Bentz
Journal:  Biophys J       Date:  2004-10-22       Impact factor: 4.033

6.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

7.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

8.  Interaction of common azole antifungals with P glycoprotein.

Authors:  Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

9.  Modeling the Kinetics of the Permeation of Antibacterial Agents into Growing Bacteria and Its Interplay with Efflux.

Authors:  Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Christophe Rousselle; Marcel Debray; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.